Jill E. Slansky

Oct 5, 2024 | nature.com | Anthony Elias |Alyse W. Staley |Monica N. Fornier |Elena Shagisultanova |Rosa I. Gallagher |Jill E. Slansky | +1 more

AbstractMost ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tumor at the time of surgery, as measured by modified preoperative endocrine predictive index (PEPI) score. Eligible patients were women with ER+/HER2− primary BC cT2 or greater. Stratification factors were clinical node and T-stage.